PTC Therapeutics to End Development of ALS Treatment

Dow Jones

2024/11/27

By Connor Hart

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.

The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated.

"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients," Chief Executive Matthew Klein said.

Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01.

ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 26, 2024 17:06 ET (22:06 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2486830143"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486830143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486830143?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 06:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486830143","market":"fut","top_or_hot":-1,"title":"PTC Therapeutics to End Development of ALS Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial. \n</p>\n<p>\n  The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated. \n</p>\n<p>\n  \"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients,\" Chief Executive Matthew Klein said. \n</p>\n<p>\n  Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01. \n</p>\n<p>\n  ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 17:06 ET (22:06 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics to End Development of ALS Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics to End Development of ALS Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-27 06:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial. \n</p>\n<p>\n  The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated. \n</p>\n<p>\n  \"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients,\" Chief Executive Matthew Klein said. \n</p>\n<p>\n  Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01. \n</p>\n<p>\n  ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 17:06 ET (22:06 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486830143","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486830143","pubTimestamp":1732658760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated.\"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients,\" Chief Executive Matthew Klein said.Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01.ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2506952337.HKD":"BNP PARIBAS CLIMATE IMPACT \"CRH\" (HKDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1721428347.USD":"BNP PARIBAS CLIMATE IMPACT \"C\" (USD) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2477742899.HKD":"BNP PARIBAS CLIMATE IMPACT \"C\" (HKD) ACC","LU2506952410.USD":"BNP PARIBAS CLIMATE IMPACT \"CRH\" (USDHDG) ACC A","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4023":"应用软件","BK4554":"元宇宙及AR概念","BK4585":"ETF&股票定投概念","BK4576":"AR","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","PTCT":"PTC Therapeutics Inc.","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","PTC":"PTC Inc."},"translate_title":"PTC Therapeutics将结束ALS治疗的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1,"PTC":1},"content_text":"By Connor Hart \n\n\n \n\n\n  PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial. \n\n\n  The Warren, N.J., biopharmaceutical company said Tuesday that the treatment, called utreloxastat, didn't meet the goal of slowing disease progression, despite having demonstrated to be safe and well tolerated. \n\n\n  \"We are of course disappointed that we were not able to demonstrate treatment efficacy and provide a potential therapy that could address the significant unmet medical need of ALS patients,\" Chief Executive Matthew Klein said. \n\n\n  Shares fell 2.7%, to $44.75, in post-market trading after ending the regular session 7% higher, at $46.01. \n\n\n  ALS, sometimes referred to as Lou Gehrig's disease, is a rare, progressive and fatal neurodegenerative disease that affects motor neurons in the brain and spinal cord. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 17:06 ET (22:06 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}